

**Supplementary Table 2.** Drug usage during anticholinergic treatment

	At initiation of AC therapy			At follow-up*			Differences		
	With AID	Without AID	<i>p</i>	With AID	Without AID	<i>p</i>	With AID	Without AID	<i>p</i>
Levodopa daily dose, mg/day	255.8 ± 80.5	263.3 ± 237.1	0.802	263.5 ± 79.5	319.0 ± 240.3	0.070	7.7 ± 27.7	55.7 ± 123.0	< 0.001
LEDD, mg/day	288.3 ± 105.3	327.6 ± 241.0	0.278	298.9 ± 99.5	381.2 ± 230.2	0.021	10.6 ± 28.8	53.6 ± 125.9	0.002
Dopamine agonist	2 (15.4)	50 (34.5)	0.223	3 (23.1)	48 (33.1)	0.551	1 (7.7)	-2 (-1.4)	> 0.999
MAO-B inhibitor	2 (15.4)	18 (12.4)	0.758	2 (15.4)	19 (13.1)	0.684	0 (0)	1 (0.7)	> 0.999
COMT inhibitor	1 (7.7)	7 (4.8)	0.505	1 (7.7)	5 (3.4)	0.443	0 (0)	-2 (-1.4)	0.687

Values are presented as mean ± standard deviation or *n* (%).

\*at onset of dyskinesia for patients with anticholinergic-induced dyskinesia and at 3 months later from initiation of anticholinergics for patients without dyskinesia.

AC, anticholinergic; AID, anticholinergic-induced dyskinesia; LEDD, levodopa-equivalent daily dose; MAO-B, monoamine oxidase B; COMT, catechol-O-methyltransferase.